{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0"},{"groupId":"OG001","value":"9.5"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7"},{"groupId":"OG001","value":"34.3"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.5"},{"groupId":"OG001","value":"44.4"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8"},{"groupId":"OG001","value":"8.9"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5"},{"groupId":"OG001","value":"2.4"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"169"}],"units":"Participants"}],"description":"An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to maximum severity grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Grade 1 =mild; Grade 2 =moderate; within normal limits, Grade 3 =severe or medically significant but not immediately life-threatening; Grade 4 =life-threatening or disabling; urgent intervention indicated; Grade 5 =death.","groups":[{"description":"Crizotinib 250 mg capsule, orally twice daily was administered in treatment cycle of 21 days. Participants could continue crizotinib treatment beyond the time of RECIST v1.1 defined PD, as determined by IRR, at the discretion of the investigator if the participant was perceived to be experiencing clinical benefit.","id":"OG000","title":"Crizotinib"},{"description":"Standard doses of chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) were administered intravenously on Day 1 of each cycle for a maximum of 6 cycles. Pemetrexed 500 mg per meter square (m)\\^2 IV infusion according to standard of care was administered over 10 min; either cisplatin 75 mg/m\\^2 IV infusion was administered approximately 30 min after the end of the pemetrexed infusion or carboplatin was administered at a dose calculated to produce an AUC of 5 or 6 mg\\*min/mL, approximately 30 min after end of pemetrexed infusion.","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The safety analysis population included all randomized subjects who received at least 1 dose of study treatment, with treatment assignments designated according to actual study treatment received during the first cycle.","reportingStatus":"POSTED","timeFrame":"Baseline up to follow up period (up to 72 months)","title":"Percentage of Participants With Adverse Events (AEs) According to Maximum Severity","type":"SECONDARY","unitOfMeasure":"percentage of participants"}